The FDA last October paused Intellia Therapeutics’ late-stage CRISPR studies after detecting life-threatening enzyme ...

Editas Medicine (NASDAQ:EDIT) executives outlined the company’s in vivo CRISPR gene-editing strategy and near-term clinical plans during a recent discussion featuring President and CEO Gilmore O’Neill ...

Rapid advancements in CRISPR and next-generation gene editing technologies, combined with a strong clinical pipeline ...

A research group led by Associate Professor Tetsuya Muramoto from the Faculty of Science, Toho University, has established a CRISPR genome editing technique that enables comparative analysis of the ...

A popular gene-editing technique may unintentionally delete and rearrange DNA bases, according to a new study published in Nature Biotechnology. The study involves the use of CRISPR-Cas9, a system ...

A recent study utilizing cryo-EM advances our understanding of how bacterial immune systems function and reveals new aspects ...

Two studies published in Nature Medicine June 11 contribute to a small body of literature suggesting cells edited with CRISPR-Cas9 may cause cancer. Here are five things to know about the studies and ...

Banas is associate director of research at the Gene Editing Institute at ChristianaCare, where Kmiec is founder and executive director. The medical promise of CRISPR gene editing can be seen most ...

The company got into the game by partnering with smaller drugmakers in this field, most notably CRISPR Therapeutics. The two ...

CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...